BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34752367)

  • 21. Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [
    Wang D; Zhang X; Liu H; Qiu B; Liu S; Zheng C; Fu J; Mo Y; Chen N; Zhou R; Chu C; Liu F; Guo J; Zhou Y; Zhou Y; Fan W; Liu H
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4692-4704. PubMed ID: 35819498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of prognostic values of primary tumor and nodal
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A; Yazici B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
    Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
    AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer.
    Park SY; Yoon JK; Park KJ; Lee SJ
    Cancer Imaging; 2015 Dec; 15():21. PubMed ID: 26694918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer.
    Hua J; Li L; Liu L; Liu Q; Liu Y; Chen X
    Nucl Med Commun; 2021 Nov; 42(11):1247-1253. PubMed ID: 34269750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Texture Analysis on [
    Bianconi F; Palumbo I; Fravolini ML; Chiari R; Minestrini M; Brunese L; Palumbo B
    Mol Imaging Biol; 2019 Dec; 21(6):1200-1209. PubMed ID: 30847822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic ability of
    Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
    Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma.
    Lu P; Sun Y; Sun Y; Yu L
    Lung Cancer; 2014 Jul; 85(1):53-8. PubMed ID: 24792334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic importance of
    Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study.
    Kanzaki R; Higashiyama M; Fujiwara A; Tokunaga T; Maeda J; Okami J; Kozuka T; Hosoki T; Hasegawa Y; Takami M; Tomita Y; Kodama K
    Lung Cancer; 2011 Mar; 71(3):333-7. PubMed ID: 20619479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
    Meng X; Sun X; Mu D; Xing L; Ma L; Zhang B; Zhao S; Yang G; Kong FM; Yu J
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):960-6. PubMed ID: 21440998
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
    Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.